Extracellular vesicles (EVs) or exosomes are subcellular entities released by cells. It is becoming widely known that exosomes are as effective as cell therapies for tissue regeneration, diseases such as stroke, heart failure, arthritis while being safer and more convenient for supply chains. Therefore, they are increasingly explored by many stakeholders.
/bucket-prod.jecreemavitrine.fr/uploads/sites/138/2022/07/Sans-titre-1-1.png)
They work with us
/bucket-prod.jecreemavitrine.fr/uploads/sites/138/2023/06/They-work-with-us.png)
EVerZom mission : working towards the democratization of exosome-based-therapies
The first dedicated exosome service company
Providing a large scale GMP manufacturing platform of exosomes
EVerZom is a spin-off from a CNRS laboratory at Paris Université who invented and patented a disruptive method to produce exosomes at high yield and large scale.
Based on this proprietary technology, EVerZom aims to establish the leading European GMP compliant exosome CDMO (Contract Development Manufacturing Organization) dedicated to exosome biotechs, research institutions and Big Pharmas.
/bucket-prod.jecreemavitrine.fr/uploads/sites/138/2022/07/Sans-titre-2.png)
A breakthrough technology
The ability to manufacture quantities of exosomes compatible with human use is a major challenge for the diffusion of this innovation. Indeed, the major hindrance to overcome for rendering exosome-based therapies clinically feasible is a cost-effective large-scale standardized production platform complying with regulatory issues and Good Manufacturing Practices (GMP). Existing production methods gives low manufacturing yields, are not all scalable and are very time consuming, rarely GMP compliant, making clinical translation of exosome-based therapeutics very difficult.
/bucket-prod.jecreemavitrine.fr/uploads/sites/138/2022/07/magical-blue-and-green-ember-particles-mystical-ha-2022-01-14-22-21-24-utc2-4.png)
/bucket-prod.jecreemavitrine.fr/uploads/sites/138/2022/07/Sans-titre-1-3.png)
EVerZom technology
A patented and disruptive method to produce exosomes at high yield and large scale. With its breakthrough technology, EVerZom is adressing this challenge and works towards the democratization of exosome-based-therapies.
/bucket-prod.jecreemavitrine.fr/uploads/sites/138/2022/07/illus-everzom-missions-home.jpg)
/bucket-prod.jecreemavitrine.fr/uploads/sites/138/2022/07/ILLUS-everzom-techno.jpg)
/bucket-prod.jecreemavitrine.fr/uploads/sites/138/2022/07/illus-offers.jpg)
-
EVerZom has developed a disruptive method to produce exosomes at high yield and large scale. The team processes to trigger massive exosome release consists in applying a turbulence stimulation on cells.
-
This technology offers key advantages such as high yield production (10 times more vesicles in 1/10th of the time for mesenchymal stem cells (MSC)), large scale, GMP compatibility and shorter process.
The ambition of EVerZom technology is to produce clinical grade/GMP exosomes services and bring these new discoveries to the patient care.
-
We offer dedicated services with our technology at any stage of development (discovery, pre-clinical, clinical). From your cells, we run engineering production tests to evaluate the yield improvement with our technology before a large scale production.
EVerZom also provide a large panel of services for exosome development like exosome production, characterization, isolation/purification and engineering services.
EVerZom services
EVerZom has developed offers, services and products dedicated to exosome biotechs, research institutions and Big Pharmas.
Exosome manufacturing services
As an exosome service company, EverZom provides to biotechs and academic institutions tailored made exosome manufacturing services. Please fill this form for more information on our production services.
EVerZom Technology
The ambition of EVerZom technology is to produce clinical grade/GMP exosomes services and bring these new discoveries to the patient care. Discover more about our processes and patented technology.
Exosome purification/isolation services
EverZom provides customized exosome isolation services to concentrate and purify supernatants and exosome samples to its partners.
Exosome characterization services and quality control
As an exosome services company, we provide exosome characterization and quality control services.
Exosome engineering services
EVerZom also provide customized services to engineer and load exosomes with proteins or nucleic acids and develops its own patented technology.
EVerZom products
EVerZom commercializes exosomes and extracellular vesicles produced from different cell types/cell lines with our turbulence technology as a standard for research or control.
Our latest scientific resources
Exosome immunogenicity
To allow its use in humans and avoid side effects/risks or loss of potency, extracellular vesicles have to be tested to know more about their immunogenicity. As an example, the…
ReadExosome stability and storage
The stability of extracellular vesicles (EVs) both before injection and after injection is a critical parameter to investigate. Once produced, extracellular vesicles have to be…
ReadSelection of the optimal cell source for extracellular vesicles production in regenerative…
Extracellular vesicles (EVs) are vesicles secreted by cells from several biogenesis pathways. Extracellular vesicles are currently developed for therapies mainly in regenerative…
ReadEVerZom latest news
Winner of the European EIC Accelerator program
EVerZom, announced today that it has obtained non-dilutive funding of €2.5 million as the winner of the European EIC Accelerator competition. This funding will enable the company to transfer its extracellular vesicle biomanufacturing technology for a first clinical grade batch production and to accelerate the scale-up of its production capabilities by developing a process compatible with clinical Phase 2/3 for the pharmaceutical industry.
/bucket-prod.jecreemavitrine.fr/uploads/sites/138/2023/03/horizon_europe.jpg)
They support us
/bucket-prod.jecreemavitrine.fr/uploads/sites/138/2023/06/They-support-us.png)